Skip to main content
. 2022 Jan 18;66(1):e01397-21. doi: 10.1128/AAC.01397-21

TABLE 2.

Activity of KBP-7072 and tetracycline class comparators against Gram-positive clinical isolates

Antimicrobial agent (no. of isolates) MIC50 (mg/liter) MIC90 (mg/liter) MIC range (mg/liter) CLSIa
%S %I %R
Staphylococcus aureus (104)
  KBP-7072 0.06 0.12 0.03–0.5
  Doxycycline 0.12 1 0.03–8 96.2 3.8 0.0
  Minocycline 0.06 0.25 0.03–16 96.2 1.9 1.9
  Omadacycline 0.12 0.25 0.06–4 97.1,b,c 97.1d,e 0.0, 0.0 2.9, 2.9
  Tetracycline 0.25 16 0.12–64 86.5 1.9 11.5
  Tigecycline 0.12 0.25 0.03–1 99.0c
S. aureus (52) methicillin susceptible
  KBP-7072 0.06 0.12 0.03–0.12
  Doxycycline 0.06 0.25 0.03–1 100.0 0.0 0.0
  Minocycline 0.06 0.25 0.03–0.25 100.0 0.0 0.0
  Omadacycline 0.12 0.25 0.06–0.25 100.0,b,c 100.0d,e 0.0, 0.0 0.0, 0.0
  Tetracycline 0.25 0.5 0.12–16 94.2 1.9 3.8
  Tigecycline 0.12 0.12 0.03–0.25 100.0c
S. aureus (52) methicillin resistant
  KBP-7072 0.06 0.12 0.03–0.5
  Doxycycline 0.12 2 0.06–8 92.3 7.7 0.0
  Minocycline 0.06 0.5 0.03–16 92.3 3.8 3.8
  Omadacycline 0.12 0.25 0.06–4 94.2,b,c 94.2d,e 0.0, 0.0 5.8, 5.8
  Tetracycline 0.25 32 0.12–64 78.8 1.9 19.2
  Tigecycline 0.12 0.25 0.06–1 98.1c
S. aureus (12) tetracycline resistant
  KBP-7072 0.06 0.25 0.03–0.5
  Doxycycline 2 8 1–8 66.7 33.3 0.0
  Minocycline 0.25 16 0.06–16 66.7 15.6 15.6
  Omadacycline 0.12 2 0.06–4 83.3,b,c 83.3d,e 0.0, 0.0 16.7, 16.7
  Tetracycline 32 64 16–64 0.0 0.0 100.0
  Tigecycline 0.12 0.5 0.12–1 91.7 8.3
S. lugdunensis (20)
  KBP-7072 0.03 0.03 ≤0.015–0.03
  Doxycycline 0.06 0.06 0.015–4 100.0 0.0 0.0
  Minocycline 0.03 0.03 ≤0.015–0.12 100.0 0.0 0.0
  Omadacycline 0.06 0.06 ≤0.015–0.06 100.0b,c 0.0 0.0
  Tetracycline 0.12 0.12 ≤0.03–64 95.0 0.0 5.0
  Tigecycline 0.03 0.06 0.015–0.12
Other coagulase-negative staphylococcif (22)
  KBP-7072 0.06 0.25 0.03–0.5
  Doxycycline 0.12 8 0.06–16 86.4 4.5 9.1
  Minocycline 0.12 0.5 0.03–1 100.0 0.0 0.0
  Omadacycline 0.12 1 0.06–1
  Tetracycline 0.25 64 0.12 to >64 81.8 0.0 18.2
  Tigecycline 0.06 0.25 0.03–0.5
Enterococcus faecalis (51)
  KBP-7072 0.03 0.06 0.03–0.06
  Doxycycline 8 8 0.12–32 45.1 49.0 5.9
  Minocycline 8 16 0.06–16 33.3 35.3 31.4
  Omadacycline 0.12 0.12 0.06–0.25 100.0b,c 0.0 0.0
  Tetracycline 32 64 0.25 to >64 31.4 0.0 68.6
  Tigecycline 0.12 0.12 0.06–0.25 100.0g
E. faecium (50)
  KBP-7072 0.03 0.03 ≤0.015–0.12
  Doxycycline 0.12 8 0.06–8 76.0 24.0 0.0
  Minocycline 0.06 16 0.03–16 70.0 10.0 20.0
  Omadacycline 0.06 0.12 0.03–0.5
  Tetracycline 0.5 >64 0.12 to >64 54.0 0.0 46.0
  Tigecycline 0.06 0.06 0.03–0.25
E. faecium (24) vancomycin nonsusceptible (MIC, ≥32 mg/liter)
  KBP-7072 0.03 0.03 ≤0.015–0.12
  Doxycycline 0.12 8 0.06–8 75.0 25.0 0.0
  Minocycline 0.06 16 0.03–16 66.7 12.5 20.8
  Omadacycline 0.06 0.12 0.03–0.5
  Tetracycline 0.25 >64 0.12 to >64 50.0 0.0 50.0
  Tigecycline 0.06 0.06 0.03–0.25
Streptococcus pneumoniae (127)
  KBP-7072 ≤0.015 0.03 ≤0.015–0.06
  Doxycycline 0.12 8 0.03–16 70.9 2.4 26.8
  Minocycline 0.12 8 0.03–32
  Omadacycline 0.03 0.06 ≤0.015–0.12 100.0b,c 0.0 0.0
  Tetracycline 0.25 64 0.12–64 72.4 0.0 27.6
  Tigecycline 0.03 0.03 0.015–0.06 100.0c
S. pneumoniae (55) erythromycin resistant (MIC, ≥1 mg/liter)
  KBP-7072 ≤0.015 0.03 ≤0.015–0.03
  Doxycycline 4 16 0.03–16 38.2 3.6 58.2
  Minocycline 4 8 0.03–32
  Omadacycline 0.03 0.06 ≤0.015–0.12 100.0b,c 0.0 0.0
  Tetracycline 32 64 0.12–64 40.0 0.0 60.0
  Tigecycline 0.03 0.03 0.015–0.06 100.0c
S. pneumoniae (24) penicillin resistant (MIC, ≥2 mg/liter) oral
  KBP-7072 ≤0.015 0.03 ≤0.015–0.03
  Doxycycline 2 8 0.03–16 41.7 0.0 58.3
  Minocycline 4 8 0.03–16
  Omadacycline 0.06 0.06 ≤0.015–0.12 100.0b,c 0.0 0.0
  Tetracycline 16 64 0.12–64 41.7 0.0 58.3
  Tigecycline 0.03 0.03 0.015–0.06 100.0c
S. pneumoniae (35) tetracycline resistant (MIC, ≥2 mg/liter)
  KBP-7072 ≤0.015 0.03 ≤0.015–0.03
  Doxycycline 8 16 0.5–16 0.0 2.9 97.1
  Minocycline 8 16 0.5–32
  Omadacycline 0.06 0.06 0.03–0.12 100.0b,c 0.0 0.0
  Tetracycline 32 64 4–64 0.0 0.0 100.0
  Tigecycline 0.03 0.03 0.015–0.06 100.0c
S. agalactiae (52)
  KBP-7072 0.03 0.06 0.03–0.06
  Doxycycline 8 16 0.12–16
  Minocycline 16 32 0.06–32
  Omadacycline 0.12 0.25 0.06–0.25
  Tetracycline 32 64 0.25–64 19.2 0.0 80.8
  Tigecycline 0.06 0.06 0.03–0.06 100.0c
S. agalactiae (22) macrolide resistant (erythromycin MIC, ≥1 mg/liter)
  KBP-7072 0.03 0.06 0.03–0.06
  Doxycycline 16 16 0.12–16
  Minocycline 16 32 0.06–32
  Omadacycline 0.12 0.25 0.06–0.25
  Tetracycline 32 64 0.25–64 4.5 0.0 95.5
  Tigecycline 0.06 0.06 0.03–0.06 100.0c
S. pyogenes (51)
  KBP-7072 0.03 0.03 ≤0.015–0.06
  Doxycycline 0.12 8 0.06–16
  Minocycline 0.12 8 0.06–16
  Omadacycline 0.06 0.12 0.03–0.25 98.0b,c 2.0 0.0
  Tetracycline 0.25 32 0.06–64 80.4 0.0 19.6
  Tigecycline 0.03 0.06 0.015–0.12 100.0c
S. anginosus group (17)
  KBP-7072 ≤0.015 0.03 ≤0.015–0.03
  Doxycycline 0.25 8 0.06–16
  Minocycline 0.06 16 ≤0.015–16
  Omadacycline 0.06 0.12 ≤0.015–0.12 100.0b,c 0.0 0.0
  Tetracycline 0.5 32 0.06–64 70.6 5.9 23.5
  Tigecycline 0.015 0.03 ≤0.008–0.06 100.0c
a

Criteria as published by CLSI (22).

b

Using ABSSSI breakpoints.

c

FDA breakpoints.

d

Using CABP breakpoints.

e

FDA breakpoints for MSSA only (applied for all S. aureus).

f

Organisms include Staphylococcus capitis (2), S. epidermidis (11), S. haemolyticus (3), S. hominis (1), S. pettenkoferi (1), S. pseudintermedius/intermedius/delphini (3), and S. simulans (1).

g

FDA breakpoints applied to all E. faecalis but approved for vancomycin-susceptible isolates only.